{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:56:47Z","timestamp":1782755807397,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-1007-1","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T08:37:14Z","timestamp":1534927034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink"],"prefix":"10.1186","volume":"19","author":[{"given":"Hans","family":"Furuland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Linde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ayoubkhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameet","family":"Bakhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Palaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"issue":"2","key":"1007_CR1","first-page":"283","volume":"73","author":"JC Hollander-Rodriguez","year":"2006","unstructured":"Hollander-Rodriguez JC, Calvert JF. Hyperkalemia. Am Fam Physician. 2006;73(2):283\u201390.","journal-title":"Am Fam Physician"},{"issue":"12","key":"1007_CR2","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"LM Einhorn","year":"2009","unstructured":"Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156\u201362.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1007_CR3","doi-asserted-by":"publisher","first-page":"c8","DOI":"10.1159\/000329511","volume":"120","author":"J Hayes","year":"2012","unstructured":"Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP. Association of hypo-and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract. 2012;120(1):c8\u201316.","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"1007_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2215\/CJN.01730215","volume":"11","author":"J Luo","year":"2016","unstructured":"Luo J, Brunelli SM, Jensen DE, Yang A. Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol. 2016;11(1):90\u2013100.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1007_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2215\/CJN.05850809","volume":"5","author":"S Korgaonkar","year":"2010","unstructured":"Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol. 2010;5(5):762\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1007_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","volume":"46","author":"AJ Collins","year":"2017","unstructured":"Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes. Am J Nephrol. 2017;46(3):213\u201321.","journal-title":"Am J Nephrol"},{"issue":"1","key":"1007_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease Improving Global Outcomes","year":"2013","unstructured":"Kidney Disease Improving Global Outcomes. KDIGO 2012 clinical practice guideline for the evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1\u2013150.","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"1007_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"27","key":"1007_CR9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"key":"1007_CR10","unstructured":"Queen Mary University of London Clinical Effectiveness Group. Summary guidelines: Heart Failure update. 2015. \n                    https:\/\/www.qmul.ac.uk\/blizard\/ceg\/media\/blizard\/documents\/ceg-documents\/Heart-Failure-Update,-Nov-2015.pdf\n                    \n                  . Accessed 25 Oct 2017."},{"issue":"Suppl 11","key":"1007_CR11","first-page":"s212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(Suppl 11):s212\u201320.","journal-title":"Am J Manag Care"},{"issue":"1","key":"1007_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","volume":"6","author":"M Epstein","year":"2016","unstructured":"Epstein M. Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney Int Suppl. 2016;6(1):20\u20138.","journal-title":"Kidney Int Suppl"},{"key":"1007_CR13","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors A, Anker S, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883\u201390.","journal-title":"Eur Heart J"},{"issue":"11","key":"1007_CR14","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/ejhf.887","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19(11):1414\u201323.","journal-title":"Eur J Heart Fail"},{"key":"1007_CR15","unstructured":"Medicines and Healthcare Products Regulatory Agency. Clinical Practice Research Datalink. 2017. \n                    https:\/\/www.cprd.com\/home\/\n                    \n                  . Accessed 19 Sept 2017."},{"issue":"3","key":"1007_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827\u201336.","journal-title":"Int J Epidemiol"},{"key":"1007_CR17","volume-title":"Hospital episode statistics","author":"NHS Digital","year":"2017","unstructured":"NHS Digital. Hospital episode statistics. 2017. \n                    http:\/\/content.digital.nhs.uk\/hes\n                    \n                  . Accessed 20 Sept 2017."},{"key":"1007_CR18","unstructured":"The R Foundation. The R Project for Statistical Computing, Vienna, Austria. 2017. \n                    https:\/\/www.R-project.org\/\n                    \n                  . Accessed 27 July 2017."},{"key":"1007_CR19","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New Jersey: Wiley; 2004."},{"issue":"1","key":"1007_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.0006-341X.2001.00120.x","volume":"57","author":"W Pan","year":"2001","unstructured":"Pan W. Akaike's information criterion in generalized estimating equations. Biometrics. 2001;57(1):120\u20135.","journal-title":"Biometrics"},{"issue":"11","key":"1007_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/qjmed\/hcx118","volume":"110","author":"W Cheungpasitporn","year":"2017","unstructured":"Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Sakhuja A, Mao MA, Erickson SB. Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease. QJM. 2017;110(11):713\u20139.","journal-title":"QJM"},{"issue":"6","key":"1007_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000437151","volume":"41","author":"GN Nakhoul","year":"2015","unstructured":"Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV Jr, et al. Serum potassium, end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol. 2015;41(6):456\u201363.","journal-title":"Am J Nephrol"},{"issue":"10","key":"1007_CR23","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","volume":"109","author":"N Jain","year":"2012","unstructured":"Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510\u20133.","journal-title":"Am J Cardiol"},{"issue":"6","key":"1007_CR24","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.ekir.2017.07.001","volume":"2","author":"PH Pun","year":"2017","unstructured":"Pun PH, Goldstein BA, Gallis JA, Middleton JP, Svetkey LP. Serum potassium levels and risk of sudden cardiac death among patients with chronic kidney disease and significant coronary artery disease. Kidney Int Rep. 2017;2(6):1122\u201331.","journal-title":"Kidney Int Rep"},{"key":"1007_CR25","unstructured":"Harshfield A, Rhodes K, Barclay S, Payne R. The accuracy of death dates recorded in the clinical practice research datalink (CPRD). Society for Academic Primary Care ASM; 2017."},{"issue":"6","key":"1007_CR26","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/ndt\/gfr696","volume":"27","author":"M Evans","year":"2012","unstructured":"Evans M, Bain SC, Hogan S, Bilous RW. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan diabetic nephropathy trial. Nephrol Dial Transplant. 2012;27(6):2255\u201363.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1007_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728\u201341.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1007_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","volume":"17","author":"G Currie","year":"2016","unstructured":"Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17(1):127.","journal-title":"BMC Nephrol"},{"issue":"4","key":"1007_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/1947-2714.110426","volume":"5","author":"JR Asirvatham","year":"2013","unstructured":"Asirvatham JR, Moses V, Bjornson L. Errors in potassium measurement: a laboratory perspective for the clinician. N Am J Med Sci. 2013;5(4):255\u20139.","journal-title":"N Am J Med Sci"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1007-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1007-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1007-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:36:41Z","timestamp":1569199001000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1007-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1007-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,22]]},"assertion":[{"value":"2 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Routinely collected, anonymised electronic health records from the Clinical Practice Research Datalink (CPRD) used as part of this study were provided by the Medicines and Healthcare Products Regulatory Agency (MHRA), an executive agency of the Department of Health & Social Care. This study was approved by the Independent Scientific Advisory Committee for MHRA database research on 15 December 2016 (study protocol 16_223R). Patient consent is covered by the CPRD privacy policy, available at\n            \n            . No other patient-level data were collected as part of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HF has received modest research grant funding from AstraZeneca (as principal investigator), and modest expert witness funding from Amgen (as consultant). PM, DA and HB have received significant research grant funding from AstraZeneca in relation to this study. ME declares no conflict of interest. CL has received significant research grant funding from AstraZeneca (awarded to institution), and modest speaker honoraria from Biotronik, Medtronic, Abbot, Novartis and Vifor. AB has received modest advisory honoraria from AstraZeneca in relation to this study. EP and LQ are full-time employees of AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"211"}}